51.
Tabbers MM, Boluyt N, Berger MY, et al. Nonpharmacologic treatments for childhood
constipation: systematic review. Pediatrics 2011;128:753-61.
52.
Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the
treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313.
53.
Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in
primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154.
54.
Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for
the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011:CD003460.
55.
Christensen MF. Recurrent abdominal pain and dietary fiber. Am J Dis Child 1986;140:738-9.
56.
Feldman W, McGrath P, Hodgson C, et al. The use of dietary fiber in the management of simple,
childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized,
controlled trial. Am J Dis Child 1985;139:1216-8.
57.
Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of
childhood constipation. Pediatrics 2004;113:e259-64.
58.
Castillejo G, Bullo M, Anguera A, et al. A controlled, randomized, double-blind trial to evaluate
the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated
pediatric patients. Pediatrics 2006;118:e641-8.
59.
Kokke FT, Scholtens PA, Alles MS, et al. A dietary fiber mixture versus lactulose in the treatment
of childhood constipation: a double-blind randomized controlled trial. J Pediatr Gastroenterol Nutr
2008;47:592-7.
60.
Romano C, Comito D, Famiani A, et al. Partially hydrolyzed guar gum in pediatric functional
abdominal pain. World J Gastroenterol 2013;19:235-40.
61.
Chiou E, Nurko S. Functional abdominal pain and irritable bowel syndrome in children and
adolescents. Therapy 2011;8:315-331.
62.
Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth
muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and
guinea pig. Gastroenterology 1991;101:55-65.
63.
Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil.
Phytomedicine 2005;12:612-6.
64.
Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint
oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385-90.
65.
Kline RM, Kline JJ, Di Palma J, et al. Enteric-coated, pH-dependent peppermint oil capsules for
the treatment of irritable bowel syndrome in children. J Pediatr 2001;138:125-8.
66.
Charrois TL, Hrudey J, Gardiner P, et al. Peppermint oil. Pediatr Rev 2006;27:e49-51.
67.
Rigsbee L, Agans R, Shankar V, et al. Quantitative Profiling of Gut Microbiota of Children With
Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol 2012.
68.
Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric
patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-91.
69.
Reid G, Younes JA, Van der Mei HC, et al. Microbiota restoration: natural and supplemented
recovery of human microbial communities. Nat Rev Microbiol 2011;9:27-38.
70.
Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable
bowel syndrome: a systematic review. GUT 2010;59:325-32.
71.
Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable
bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-49; quiz 1050.
72.
Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in
the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15.
73.
McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel
syndrome. World J Gastroenterol 2008;14:2650-61.
74.
Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel
syndrome. J Clin Gastroenterol 2011;45 Suppl:S145-8.
75.
Francavilla R, Miniello V, Magista AM, et al. A randomized controlled trial of Lactobacillus GG in
children with functional abdominal pain. Pediatrics 2010;126:e1445-52.
76.
Gawronska A, Dziechciarz P, Horvath A, et al. A randomized double-blind placebo-controlled trial
of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-84.
77.
Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a
double-blind randomized control trial. J Pediatr 2005;147:197-201.
78.
Guandalini S, Magazzu G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable
bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J
Pediatr Gastroenterol Nutr 2010;51:24-30.
79.
Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger
Med Sci 2010;8:Doc07.
80.
Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium
lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics
2011;127:e1392-9.
81.
Bu LN, Chang MH, Ni YH, et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic
constipation. Pediatr Int 2007;49:485-90.
82.
Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with
Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol
2011;17:3916-21.
83.
Vandenplas Y, Benninga M. Probiotics and functional gastrointestinal disorders in children. J
Pediatr Gastroenterol Nutr 2009;48 Suppl 2:S107-9.
84.
Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS)
and what they would like to know. National Survey on Patient Educational Needs in IBS and
development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol
2007;102:1972-82.
85.
Malaty HM, Abudayyeh S, Fraley K, et al. Recurrent abdominal pain in school children: effect of
obesity and diet. Acta Paediatr 2007;96:572-6.
86.
Svedberg P, Johansson S, Wallander MA, et al. Extra-intestinal manifestations associated with
irritable bowel syndrome: a twin study. Aliment.Pharmacol.Ther. 2002;16:975-983.
87.
Teitelbaum JE, Sinha P, Micale M, et al. Obesity is related to multiple functional abdominal
diseases. J Pediatr 2009;154:444-6.
88.
Porcelli P, Leandro G, De Carne M. Functional gastrointestinal disorders and eating disorders.
Relevance of the association in clinical management. Scand J Gastroenterol 1998;33:577-82.
89.
Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin
North Am 2005;34:247-55.
90.
Deloose E, Janssen P, Depoortere I, et al. The migrating motor complex: control mechanisms and
its role in health and disease. Nat Rev Gastroenterol Hepatol 2012;9:271-85.
91.
Simren M, Abrahamsson H, Bjornsson ES. An exaggerated sensory component of the
gastrocolonic response in patients with irritable bowel syndrome. GUT 2001;48:20-27.
92.
Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the
irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation
during a prospective 6-week study. Eur.J Gastroenterol Hepatol 1998;10:415-421.
93.
Simren M, Abrahamsson H, Bjornsson ES. Lipid-induced colonic hypersensitivity in the irritable
bowel syndrome: the role of bowel habit, sex, and psychologic factors. Clin.Gastroenterol Hepatol.
2007;5:201-208.
94.
Hunt JN, Stubbs DF. The volume and energy content of meals as determinants of gastric
emptying. J Physiol 1975;245:209-25.
95.
Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic,
insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab
2006;91:2062-7.
96.
Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal
symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral
nociception hypersensitivity. Neurogastroenterol Motil 2009;21:23-32.
97.
De Schepper HU, Cremonini F, Chitkara D, et al. Assessment of gastric accommodation: overview
and evaluation of current methods. Neurogastroenterol Motil 2004;16:275-85.
98.
Jarrett M, Visser R, Heitkemper M. Diet triggers symptoms in women with irritable bowel
syndrome. The patient's perspective. Gastroenterol Nurs 2001;24:246-52.
99.
Hadley SJ, Walsh BT. Gastrointestinal disturbances in anorexia nervosa and bulimia nervosa.
Curr Drug Targets CNS Neurol Disord 2003;2:1-9.
100. Chami TN, Andersen AE, Crowell MD, et al. Gastrointestinal symptoms in bulimia nervosa:
effects of treatment. American Journal of Gastroenterology 1995;90:88-92.
101. Van Tilburg MA, Fortunato J, Squires M, et al. Diet restriction may be associated with
disturbances in GI physiology in adolescents with IBS: A pilot study. American Journal of
Gastroenterology 2011;106:S515-516.